[Management and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Results of a French national opinion survey].
OBJECTIVE
To assess the clinical and epidemiological characteristics of chronic inflammatory demyelinating polyneuropathy (CIDP) in a French population opinion survey.


METHODS
A national and multicentric metropolitan French opinion survey was conducted by TNS Healthcare Sofres from October to December 2006. Five thousand and thirty three hospital or private practice physicians were contacted by mail. A specific questionnaire (38 questions) was designed for the survey to evaluate epidemiology, diagnosis and treatment of CIDP.


RESULTS
Four hundred and forty one responses were obtained, 430 were analyzed, 11 being excluded. Only 172 physicians were caring for patients with CIDP, the others feeling that they were not competent for this management (only 34% of the physicians cared for at least one patient during the study). Treatment was managed by only 28% of the physicians and mainly by neurologists working in public hospitals. The percentage of treated patients was 84%, the others were not treated because the impairment was too mild. IVIg were the first intention treatment for 63.2% of the patients and steroids for 30.8% of them. The choice was mainly based on the good tolerance profile of IVIg, both treatments being considered as efficacious.


CONCLUSIONS
This survey has shown a higher incidence and prevalence of CIDP than expected but a methodological bias may have led to an overestimation (a same patient being included twice). Treatment complied with recommendations and guidelines while the diagnosis may be improved.
Azulay
J-P
JP
Service de neurologie, pôle neurosciences cliniques, hôpital de la Timone, 265, rue Saint-Pierre, 13385 Marseille cedex 05, France. jean-philippe.azulay@mail.ap-hm.fr
Puget
S
S
Goulamhoussen
N
N
Pouget
J
J
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D004568:Electrodiagnosis; D004576:Electromyography; D005602:France / Q000453:epidemiology; D019538:Health Care Surveys; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D010821:Physicians, Family; D020277:Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy*; D013256:Steroids / Q000627:therapeutic use; D011795:Surveys and Questionnaires
D000893:Anti-Inflammatory Agents; D016756:Immunoglobulins, Intravenous; D013256:Steroids